Close

Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300

April 15, 2024 10:32 AM EDT

Biohaven Pharma (NYSE: BHVN) disclosed:


David Spiegel, M.D. Ph.D., inventor of Biohaven Ltd.’s (“Biohaven”) MoDE technology and Professor of Chemistry at Yale University, will present an update on Biohaven’s degrader platform and summary of progress to date in the Phase 1 single ascending dose (“SAD”) study for BHV-1300 (“the Presentation”) at the ABI Conference 2024 in Cambridge, United Kingdom starting today (April 15-17).


A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference. The Presentation includes a summary of the BHV-1300 SAD program to date on Slide 12.




Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Hot FDA News